{"filing":{"accession_number":"0001628280-26-052150","cik":"0001736730","ticker":"CAMP","company_name":"Camp4 Therapeutics Corp","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-03","primary_document":"camp-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026052150/camp-20260803.htm"},"events":[{"id":24020,"run_id":21727,"accession_number":"0001628280-26-052150","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Camp4 Therapeutics completed the second closing of a private placement on August 3, 2026, issuing 10,756,498 shares at $1.53 per share, 39,306 insider shares at $1.65 per share, and 21,925,368 pre-funded warrants at $1.5299 per warrant, generating approximately $50.1 million in gross proceeds. The securities were sold under Section 4(a)(2) exemption without registration under the Securities Act of 1933, resulting in material dilution to existing shareholders.","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24402,"accession_number":"0001628280-26-052150","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Camp4 Therapeutics completed the second closing of a private placement on August 3, 2026, issuing 10,756,498 shares at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 per warrant, generating approximately $50.1 million in gross proceeds. This is a material unregistered equity issuance (private placement) that dilutes existing shareholders, with the securities sold under exemption from Securities Act registration requirements. The filing explicitly notes the securities \"have not been registered under the Securities Act of 1933\" and were sold in a transaction \"not involving a public offering.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:10.524023+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24403,"accession_number":"0001628280-26-052150","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Camp4 Therapeutics completed the second closing of a private placement, issuing 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to insiders, and 21,925,368 pre-funded warrants for approximately $50.1 million in gross proceeds. The securities were sold under Section 4(a)(2) exemption without registration under the Securities Act, and restrictive legends were affixed. This is a classic dilutive private placement raising material capital for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:10.524023+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24404,"accession_number":"0001628280-26-052150","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Camp4 Therapeutics announced the second closing of a private placement generating $50.1 million in gross proceeds through the sale of 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to insiders, and 21,925,368 pre-funded warrants at $1.5299 each. The filing explicitly states the securities \"were sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933,\" which is the hallmark of a dilutive unregistered equity issuance. This capital raise is material to investors as it substantially increases share count and dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:10.524023+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24402,"accession_number":"0001628280-26-052150","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Camp4 Therapeutics completed the second closing of a private placement on August 3, 2026, issuing 10,756,498 shares at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 per warrant, generating approximately $50.1 million in gross proceeds. This is a material unregistered equity issuance (private placement) that dilutes existing shareholders, with the securities sold under exemption from Securities Act registration requirements. The filing explicitly notes the securities \"have not been registered under the Securities Act of 1933\" and were sold in a transaction \"not involving a public offering.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:10.524023+00:00","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-08-04"},{"id":24403,"accession_number":"0001628280-26-052150","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Camp4 Therapeutics completed the second closing of a private placement, issuing 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to insiders, and 21,925,368 pre-funded warrants for approximately $50.1 million in gross proceeds. The securities were sold under Section 4(a)(2) exemption without registration under the Securities Act, and restrictive legends were affixed. This is a classic dilutive private placement raising material capital for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:10.524023+00:00","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-08-04"},{"id":24404,"accession_number":"0001628280-26-052150","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Camp4 Therapeutics announced the second closing of a private placement generating $50.1 million in gross proceeds through the sale of 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to insiders, and 21,925,368 pre-funded warrants at $1.5299 each. The filing explicitly states the securities \"were sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933,\" which is the hallmark of a dilutive unregistered equity issuance. This capital raise is material to investors as it substantially increases share count and dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:39:10.524023+00:00","company_name":"Camp4 Therapeutics Corp","ticker":"CAMP","filing_date":"2026-08-04"}]}